Welcome to our dedicated page for KESTRA MED TECHNOLOGIES SEC filings (Ticker: KMTS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Clinical-trial milestones, FDA clearance updates, and capital needs make Kestra Medical Technologies’ disclosures unusually dense. Investors who search “Kestra Medical Technologies insider trading Form 4 transactions” or try to mine a 200-page prospectus know the challenge of locating critical details on the ASSURE WCD and broader Cardiac Recovery System platform.
Stock Titan’s AI converts complexity into clarity. Our engine provides understanding Kestra Medical Technologies SEC documents with AI, delivering real-time alerts the moment a Kestra Medical Technologies Form 4 insider transactions real-time notice posts to EDGAR. Looking for the latest Kestra Medical Technologies quarterly earnings report 10-Q filing? We highlight revenue, R&D spend, and device adoption in minutes. Each Kestra Medical Technologies 8-K material events explained entry is tagged so you can assess FDA submissions or partnership news without wading through legal prose.
The platform also surfaces the Kestra Medical Technologies annual report 10-K simplified, breaking down clinical evidence, manufacturing capacity, and cash runway. Dashboards merge Kestra Medical Technologies earnings report filing analysis with executive pay figures from the Kestra Medical Technologies proxy statement executive compensation sections. Need trading context? Track every Kestra Medical Technologies executive stock transactions Form 4 to gauge insider sentiment. With AI-powered summaries, expert commentary, and comprehensive coverage of all filing types, you move from raw disclosure to confident decisions—no medical-device jargon required.
Jeffrey Lawrence Schwartz, a partner at Bain Capital Investors and a director/10% owner of Kestra Medical Technologies, acquired 10,909 restricted stock units (RSUs) on 09/04/2025. Each RSU converts to one common share and the RSUs vest on 09/04/2026 subject to continued service. After the reported acquisition Mr. Schwartz beneficially owns 10,909 shares directly and 27,019,225 shares indirectly, the latter held by Bain Charger Holdings, L.P. and West Affum Holdings, L.P., with Bain Capital entities holding controlling interests. Mr. Schwartz disclaims beneficial ownership except to the extent of his pecuniary interest.
Elizabeth Kwo, a director of Kestra Medical Technologies, Ltd. (KMTS), was granted 10,909 restricted stock units (RSUs) on 09/04/2025. Each RSU converts into one common share and the award will vest on 09/04/2026 provided Ms. Kwo remains in service through that date. The Form 4 was filed as an individual filing and signed by an attorney-in-fact, Traci S. Umberger, on 09/08/2025. This disclosure reports a non-derivative equity grant to an insider rather than a market sale or open-market purchase; no option exercise, sale price, or cash consideration is reported.
Elizabeth Kwo, a director of Kestra Medical Technologies, Ltd. (KMTS), reported ownership of 10,909 restricted stock units (RSUs). The RSUs each convert into one common share and are scheduled to vest on 09/04/2026, subject to her continued service. The Form 3 was filed following an event on 09/03/2025 and is the initial statement disclosing her direct beneficial ownership of these non-derivative securities.
FAQ
What is the current stock price of KESTRA MED TECHNOLOGIES (KMTS)?
What is the market cap of KESTRA MED TECHNOLOGIES (KMTS)?
